Compare TNON & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNON | PMCB |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | 26 | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 8.2M |
| IPO Year | N/A | 2001 |
| Metric | TNON | PMCB |
|---|---|---|
| Price | $0.69 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 62.5K | ★ 324.8K |
| Earning Date | 05-05-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 277.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $65.95 | N/A |
| Revenue Next Year | $50.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $0.63 |
| 52 Week High | $2.48 | $1.51 |
| Indicator | TNON | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 36.95 | 52.85 |
| Support Level | $0.66 | $0.66 |
| Resistance Level | $0.82 | $1.01 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 6.09 | 45.79 |
Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.